Budget Impact Analysis of Macimorelin, an Oral Growth Hormone Stimulation Test, As a Diagnostic Test for Adult Growth Hormone Deficiency (AGHD) across 5 European Countries

Previous PostHealth economic modelling approaches in cell and gene therapies
Next PostThe burden of adult growth hormone deficiency diagnostic tests: results of a patient experience survey in the UK